Business
InMed's INM-901 Significantly Reduces Neuroinflammation in Alzheimer's Disease Ex Vivo Study
Demonstrates statistically significant reduction of pro-inflammatory cytokines, including IL-6, IL-1β, IL-2, and KC/GroSignificantly reduces levels of inflammasome marker, NLRP3, a key contributor to neurodegenerationReduces key pro-inflammatory markers, independent of amyloid beta or tau pathologyVancouver, British Columbia--(Newsfile Corp. - June 24, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprie
About this update from Inmed Pharmaceuticals Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Demonstrates statistically significant reduction of pro-inflammatory cytokines, including IL-6, IL-1β, IL-2, and KC/Gro","length":119,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Significantly reduces levels of inflammasome marker, NLRP3, a key contributor to neurodegeneration","length":98,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Reduces key pro-inflammatory markers, independent of amyloid beta or tau pathology","length":82,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":299,"olType":false},{"type":"text","content":"Vancouver, British Columbia--(Newsfile Corp. - June 24, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced new preclinical data demonstrating that INM-901 significantly reduces inflammation in ex vivo models of neuroinflammation, further supporting its potential as a therapeutic candidate in Alzheimer's disease.","length":527,"tagName":"p"},{"type":"text","content":"The study evaluated INM-901 in an ex vivo model of lipopolysaccharide (LPS)-induced inflammation in animal brain tissue, which is designed to induce a strong expression of pro-inflammatory cytokines IL-6, IL-1β, IL-2, and KC/Gro and inflammasome marker NLRP3. Results demonstrated that INM-901 treatment can reduce pro-inflammatory cytokines and may have a direct impact on neuroinflammation independent of the influence of amyloid beta or tau aggregation. This study model offers insight into INM-901's potential therapeutic impact on brain inflammation that may underlie a broad range of neurodegenerative diseases, including Alzheimer's disease.","length":656,"tagName":"p"},{"type":"text","content":"Key Findings from the Study:","length":28,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"INM-901 significantly reduced levels of NLRP3 and IL-1β, two inflammasome markers increasingly implicated in the pathogenesis of Alzheimer's disease and other neuroinflammatory diseases.","length":190,"tagName":"p"}]},{"val":[{"type":"text","content":"INM-901 treatment resulted in a dose-dependent and statistically significant redu...